Ruzinurad

DB19209InvestigationalSmall molecule

Ruzinurad is under investigation in clinical trial NCT04956432 (A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout).

Mechanism: Pharmacologically active on Solute carrier family 22 member 12
Curator reviewed
Formula / weight: C₁₄H₁₂BrNO₂S · 338.22 g/mol (avg)
Also known as: 1-((6-bromo-4-quinolinyl)thio)cyclobutanecarboxylic acid · Cyclobutanecarboxylic acid, 1-((6-bromo-4-quinolinyl)thio)-
Code names: SHR-4640

Resolves to

Compound

UNIIUP8J9CA76ICAS1638327-48-6ChEMBLCHEMBL3746329

Structure

InChIKeyQGBWIYLNOBYNDL-UHFFFAOYSA-NSMILESOC(=O)C1(CCC1)SC1=CC=NC2=CC=C(Br)C=C12

Targets

Q96S37SLC22A12

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

16Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ruzinurad, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account